EWEdwards Lifesciences Corp

NYSE edwards.com


$ 92.42 $ -1.19 (-1.27 %)    

Friday, 28-Jun-2024 15:45:41 EDT
QQQ $ 480.73 $ -2.67 (-0.55 %)
DIA $ 390.46 $ -2.58 (-0.66 %)
SPY $ 544.98 $ -2.66 (-0.48 %)
TLT $ 92.14 $ -1.59 (-1.7 %)
GLD $ 215.05 $ -0.89 (-0.41 %)
$ 93.34
$ 93.61
$ 92.38 x 100
$ 120.00 x 102
$ 92.24 - $ 93.94
$ 60.57 - $ 96.12
3,309,489
na
56.39B
$ 1.16
$ 39.88
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-29-2024 03-31-2024 10-Q
2 02-12-2024 12-31-2023 10-K
3 10-27-2023 09-30-2023 10-Q
4 07-28-2023 06-30-2023 10-Q
5 04-28-2023 03-31-2023 10-Q
6 02-13-2023 12-31-2022 10-K
7 10-28-2022 09-30-2022 10-Q
8 07-29-2022 06-30-2022 10-Q
9 04-28-2022 03-31-2022 10-Q
10 02-14-2022 12-31-2021 10-K
11 10-29-2021 09-30-2021 10-Q
12 07-30-2021 06-30-2021 10-Q
13 04-28-2021 03-31-2021 10-Q
14 02-12-2021 12-31-2020 10-K
15 10-26-2020 09-30-2020 10-Q
16 07-27-2020 06-30-2020 10-Q
17 04-28-2020 03-31-2020 10-Q
18 02-14-2020 12-31-2019 10-K
19 10-25-2019 09-30-2019 10-Q
20 07-26-2019 06-30-2019 10-Q
21 04-26-2019 03-31-2019 10-Q
22 02-15-2019 12-31-2018 10-K
23 10-26-2018 09-30-2018 10-Q
24 07-27-2018 06-30-2018 10-Q
25 04-27-2018 03-31-2018 10-Q
26 02-16-2018 12-31-2017 10-K
27 10-27-2017 09-30-2017 10-Q
28 07-28-2017 06-30-2017 10-Q
29 04-28-2017 03-31-2017 10-Q
30 02-17-2017 12-31-2016 10-K
31 10-28-2016 09-30-2016 10-Q
32 07-29-2016 06-30-2016 10-Q
33 04-29-2016 03-31-2016 10-Q
34 02-19-2016 12-31-2015 10-K
35 10-29-2015 09-30-2015 10-Q
36 07-29-2015 06-30-2015 10-Q
37 04-29-2015 03-31-2015 10-Q
38 02-20-2015 12-31-2014 10-K
39 10-31-2014 09-30-2014 10-Q
40 08-04-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 edwards-lifesciences-presents-5-year-follow-up-data-from-partner-trials-showing-clinical-outcomes-for-female-and-small-annulus-patients-with-transcatheter-aortic-valve-replacement--at-the-new-york-valves-2024-the-structural-heart-summit

Edwards Lifesciences (NYSE:EW) today announced the results from an analysis of data from the PARTNER Trials examining outcomes ...

 bd-bolsters-portfolio-with-42b-cash-deal-for-edwards-lifesciences-critical-care-group-details

BD (Becton, Dickinson and Company) will acquire Edwards Lifesciences' Critical Care product group for $4.2 billion in cash....

Core News & Articles

Critical Care has approximately 4,500 employees with most based in Irvine, California. In 2023, the business generated more tha...

Core News & Articles

With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care. Edwards will use the aft...

 goldman-sachs-initiates-coverage-on-edwards-lifesciences-with-buy-rating-announces-price-target-of-107

Goldman Sachs analyst David Roman initiates coverage on Edwards Lifesciences (NYSE:EW) with a Buy rating and announces Price...

 citigroup-upgrades-edwards-lifesciences-to-buy-raises-price-target-to-105

Citigroup analyst Joanne Wuensch upgrades Edwards Lifesciences (NYSE:EW) from Neutral to Buy and raises the price target fro...

 indian-rival-meril-accuses-edwards-lifesciences-of-anti-competitive-behavior-in-eu-antitrust-complaint

Edwards Lifesciences faces EU antitrust complaint from Meril over patent disputes, intensifying regulatory scrutiny. Recent act...

 deutsche-bank-upgrades-edwards-lifesciences-to-buy-raises-price-target-to-103

Deutsche Bank analyst Pito Chickering upgrades Edwards Lifesciences (NYSE:EW) from Hold to Buy and raises the price target f...

 edwards-lifesciences--targeted-in-eu-antitrust-complaint-merils-complaint-singles-out-edwards-lifesciences-patent-practices-edwards-says-merils-eu-complaint-aims-to-circumvent-competition-national-court-decisions

- Reuters

 barclays-maintains-overweight-on-edwards-lifesciences-raises-price-target-to-101

Barclays analyst Matt Miksic maintains Edwards Lifesciences (NYSE:EW) with a Overweight and raises the price target from $10...